(Abstract #366104)
Session Type: Poster Session
Date: Monday, June 6, 2022
Time: 8:00-11:00 a.m. CDT
This is the first breast cancer risk model to include breast density, family history and a polygenic risk score (PRS) based on genetically determined ancestry that is validated for diverse populations. The addition of PRS substantially improved risk stratification over TCv8 alone and may allow for a more personalized approach to breast cancer risk reduction.
Download now
(Abstract #377784))
Session Type: Poster Discussion
Time: 4:30-6:00 p.m.; 1:15-4:15 p.m. CDT
In this population of women who had multigene panel testing, pathogenic variants in BRCA1, BRCA2, PALB2, RAD51C, RAD51D, and BARD1 were associated with substantial risk of triple-negative breast cancer (TNBC). There were no significant differences in pathogenic variant associated TNBC risks across ancestries. TNBC was reported more frequently in women of African ancestry.
(Abstract #364894)
This exploratory analysis evaluated the ability of ≥ 33 or ≥ 42 genomic instability score (GIS) thresholds to predict response to platinum-based treatment in patients with triple-negative breast cancer. This study of 204 tumors of mixed BRCA wild-type, BRCA mutations and unknown showed that a GIS of ≥ 33 may be the most appropriate threshold to predict response to platinum-based treatment in patients with TNBC; however, a prospective trial is needed.
(Abstract #371368)
Time: 8:00 -11:00 a.m. CDT
In this cohort of patients, even when accounting for other clinical factors such as node status, tumor grade, age at diagnosis, and other variables, Myriad’s EndoPredict® Breast Cancer Prognostic Test provided significant information for clinical decisions on extended endocrine therapy.
Precise Oncology Solutions provides a streamlined testing experience that gives you the ability to receive results for comprehensive germline testing, tumor profiling and companion diagnosic options, including HRD† testing with one order.
† For patients with ovarian cancer